2Allaudeen H,Ramaswam M,Radhakrishnan B,et al.Orally active insulin:a single insulin conjugate selected for future studies[J].Diabetes,1999,48(Syppl):A105.
4Gerber RA,Cappelleri JC,Kourides IA,et al.Improved patient satisfaction with inhaled insulin in subjects with type 1 DM:results from a multicenter randomized controlled trial[J].Diabetes,1999,48(Suppl):A13.
3[1]Janssen JA,Lamberts SW. Circulating IGF-1 and its protective rolein the pathogenesis of diabetic angiopathy. Clin Endocrinol(Oxf),2000,52( 1 ): 1
4[2]Ferry Jr RJ,Cerri RW,Cohen P. Insulin-like growth factor bindingproteins: new proteins, new functions. Horm Res, 1999,51 ( 2 ): 53
5[3]Rajaram SJ,Baylink DJ,Mohan S. Insulin-like growth factor binding proteins in serum and other biological fluids: regulation endfunction. Endocrinol Rev, 1997,18 ( 6 ): 801
6[4]Gibson JM,Westwood M, Crosby SR,et al. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 innoninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab,1995,80(4): 1369
7[5]Zaibi MS,Padieu P,Chessebeuf-Padieu M,et al. Mefformin inducesand agonist-specific increase in albumin production by primary cultured rat hepatocytes. Biochem Pharmacol, 1995,50( 6 ): 775
8[1]Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the β -cell sulfonylurea receptor Ⅰ. Binding charatteristics[J]. Biochim Biophys Acta,1994; 1191:267-277.
9[2]Kramer W, Muller G, Girbig F, et al. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor Ⅱ. Photoaffinity labeling of a 65 kDa protein by [3H] glimepiride[J]. Biochim Biophys Acta, 994;1191:278-290.
10[3]Sonnenberg GE, Garg DC, Weidler DJ, et al. Short-terrn comparison of once-versus twice-daily administration of glimepiride in patient with non-insulin-dependent diabetes mellitus[J]. Am Pharmacother,1997;31:671-676.
